Update on gene therapy for immunodeficiencies

Clinical Immunology

Volumn 135, Issue 2, 2010, Pages 247-254

  Kohn, Donald B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Hematopoietic stem cell transplant; Primary immune deficiencies

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; CD40 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE 3; LENTIVIRUS VECTOR; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; RETROVIRUS VECTOR; VIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; JAK3 DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYMOMA; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; RETROVIRIDAE;

EID: 77950690992     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.12.003     Document Type: Review

References (56)

1. Gatti R.A., Meuwissen H.J., Allen H.D., Hong R., and Good R.A. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2 (1968) 1366-1369
2. Bach F.H., Albertini R.J., Joo P., Anderson J.L., and Bortin M.M. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2 (1968) 1364-1366
3. Antoine C., Müller S., Cant A., Cavazzana-Calvo M., Veys P., Vossen J., Fasth A., Heilmann C., Wulffraat N., Seger R., Blanche S., Friedrich W., Abinun M., Davies G., Bredius R., Schulz A., Landais P., Fischer A., and European Group for Blood and Marrow Transplantation. European Society for Immunodeficiency, long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 (2003) 553-560
4. Griffith L.M., Cowan M.J., Kohn D.B., Notarangelo L.D., Puck J.M., Schultz K.R., Buckley R.H., Eapen M., Kamani N.R., O'Reilly R.J., Parkman R., Roifman C.M., Sullivan K.E., Filipovich A.H., Fleisher T.A., and Shearer W.T. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J. Allergy Clin. Immunol. 122 (2008) 1087-1096
5. Williams D.A., Lemischka I.R., Nathan D.G., and Mulligan R.C. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310 (1984) 476-480
6. Dick J.E., Magli M.C., Huszar D., Phillips R.A., and Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42 (1985) 71-79
7. Rosenberg S.A., Anderson W.F., Blaese R.M., Hwu P., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Ettinghausen S.E., et al. The development of gene therapy for the treatment of cancer. Ann. Surg. 218 (1993) 455-463
8. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A., and Anderson W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270 (1995) 475-480
9. Giblett E.R., Anderson J.E., Cohen F., Pollara B., and Meuwissen H.J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2 (1972) 1067-1069
10. Wiginton D.A., Adrian G.S., Friedman R.L., Suttle D.P., and Hutton J.J. Cloning of cDNA sequences of human adenosine deaminase. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 7481-7485
11. Miller A.D., and Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6 (1986) 2895-2902
12. Muul L.M., Tuschong L.M., Soenen S.L., Jagadeesh G.J., Ramsey W.J., Long Z., Carter C.S., Garabedian E.K., Alleyne M., Brown M., Bernstein W., Schurman S.H., Fleisher T.A., Leitman S.F., Dunbar C.E., Blaese R.M., and Candotti F. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101 (2003) 2563-2569
13. Bordignon C., Notarangelo L.D., Nobili N., Ferrari G., Casorati G., Panina P., Mazzolari E., Maggioni D., Rossi C., Servida P., Ugazio A.G., and Mavilio F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270 (1995) 470-475
14. Aiuti A., Vai S., Mortellaro A., Casorati G., Ficara F., Andolfi G., Ferrari G., Tabucchi A., Carlucci F., Ochs H.D., Notarangelo L.D., Roncarolo M.G., and Bordignon C. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med. 8 (2002) 423-425
15. Onodera M., Ariga T., Kawamura N., Kobayashi I., Ohtsu M., Yamada M., Tame A., Furuta H., Okano M., Matsumoto S., Kotani H., McGarrity G.J., Blaese R.M., and Sakiyama Y. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91 (1998) 30-36
16. Brenner M.K., Rill D.R., Moen R.C., Krance R.A., Mirro Jr. J., Anderson W.F., and Ihle J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341 (1993) 85-86
17. Hoogerbrugge P.M., van Beusechem V.W., Fischer A., Debree M., le Deist F., Perignon J.L., Morgan G., Gaspar B., Fairbanks L.D., Skeoch C.H., Moseley A., Harvey M., Levinsky R.J., and Valerio D. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3 (1996) 179-183
18. Kohn D.B., Weinberg K.I., Nolta J.A., Heiss L.N., Lenarsky C., Crooks G.M., Hanley M.E., Annett G., Brooks J.S., El-Khoureiy A., Lawrence K., Wells S., Shaw K., Moen R.C., Bastian J., Williams-Herman D.E., Elder M., Wara D., Bowen T., Hershfield M.S., Mullen C.A., Blaese R.M., and Parkman R. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nat. Med. 1 (1995) 1017-1026
19. Miller A.D., Garcia J.V., von Suhr N., Lynch C.M., Wilson C., and Eiden M.V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65 (1991) 2220-2224
20. + CD38-human hematopoietic progenitors assessed in immune-deficient mice. Blood 91 (1998) 1243-1255
21. Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., and Williams D.A. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2 (1996) 876-882
22. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., and Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
23. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., Scaramuzza S., Andolfi G., Mirolo M., Brigida I., Tabucchi A., Carlucci F., Eibl M., Aker M., Slavin S., Al-Mousa H., Al Ghonaium A., Ferster A., Duppenthaler A., Notarangelo L., Wintergerst U., Buckley R.H., Bregni M., Marktel S., Valsecchi M.G., Rossi P., Ciceri F., Miniero R., Bordignon C., and Roncarolo M.G. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360 (2009) 447-458
24. Gaspar H.B., Bjorkegren E., Parsley K., Gilmour K.C., King D., Sinclair J., Zhang F., Giannakopoulos A., Adams S., Fairbanks L.D., Gaspar J., Henderson L., Xu-Bayford J.H., Davies E.G., Veys P.A., Kinnon C., and Thrasher A.J. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14 (2006) 505-513
25. Shaw K.L., Sokolic R., Choi C., et al. Immune reconstitution after gene therapy for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID). 12th Annual Meeting of the American Society of Gene Therapy. San Diego, California, May 27- 30 (2009)
26. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., McBride O.W., and Leonard W.J. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73 (1993) 147-157
27. Hacein-Bey H., Cavazzana-Calvo M., Le Deist F., Dautry-Varsat A., Hivroz C., Rivière I., Danos O., Heard J.M., Sugamura K., Fischer A., and De Saint Basile G. Gamma-c gene transfer into SCID × 1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 87 (1996) 3108-3116
28. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Le Deist F., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
29. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., and Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346 (2002) 1185-1193
30. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., Brouns G., Schmidt M., von Kalle C., Barington T., Jakobsen M.A., Christensen H.O., Al Ghonaium A., White H.N., Smith J.L., Levinsky R.J., Ali R.R., Kinnon C., and Thrasher A.J. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
31. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348 (2003) 226-255
32. Hacein-Bey-Abina S., von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.L., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. M, LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
33. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., MacIntyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., and Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118 (2008) 3132-3142
34. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., D de Ridder K.C., Gilmour S., Adams S.I., Thornhill K.L., Parsley F.J., Staal R.E., Gale D.C., Linch J., Bayford L., Brown M., Quaye C., Kinnon P., Ancliff D.K., Webb M., Schmidt C., von Kalle H.B., and Gaspar A.J. Thrasher, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118 (2008) 3143-3150
35. Chinen J., Davis J., De Ravin S.S., Hay B.N., Hsu A.P., Linton G.F., Naumann N., Nomicos E.Y., Silvin C., Ulrick J., Whiting-Theobald N.L., Malech H.L., and Puck J.M. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 110 (2007) 67-73
36. Malech H.L., Maples P.B., Whiting-Theobald N., Linton G.F., Sekhsaria S., Vowells S.J., Li F., Miller J.A., DeCarlo E., Holland S.M., Leitman S.F., Carter C.S., Butz R.E., Read E.J., Fleisher T.A., Schneiderman R.D., Van Epps D.E., Spratt S.K., Maack C.A., Rokovich J.A., Cohen L.K., and Gallin J.I. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12133-12138
37. + cells. Blood 92 (1998) 690
38. Barese C.N., Goebel W.S., and Dinauer M.C. Gene therapy for chronic granulomatous disease. Expert Opin. Biol. Ther. 4 (2004) 1423-1434
39. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., Glimm H., Kühlcke K., Schilz A., Kunkel H., Naundorf S., Brinkmann A., Deichmann A., Fischer M., Ball C., Pilz I., Dunbar C., Du Y., Jenkins N.A., Copeland N.G., Lüthi U., Hassan M., Thrasher A.J., Hoelzer D., von Kalle C., Seger R., and Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12 (2006) 401-409
40. Bauer Jr. T.R., and Hickstein D.D. Gene therapy for leukocyte adhesion deficiency. Curr. Opin. Mol. Ther. 2 (2000) 383-388
41. Bauer Jr. T.R., Allen J.M., Hai M., Tuschong L.M., Khan I.F., Olson E.M., Adler R.L., Burkholder T.H., Gu Y.C., Russell D.W., and Hickstein D.D. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat. Med. 14 (2008) 93-97
42. Parkman R., Rappeport J., Geha R., Belli J., Cassady R., Levey R., Nathan D.G., and Rosen F.S. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N. Engl. J. Med. 298 (1978) 921-927
43. Filipovich A.H., Stone J.V., Tomany S.C., Ireland M., Kollman C., Pelz C.J., Casper J.T., Cowan M.J., Edwards J.R., Fasth A., Gale R.P., Junker A., Kamani N.R., Loechelt B.J., Pietryga D.W., Ringdén O., Vowels M., Hegland J., Williams A.V., Klein J.P., Sobocinski K.A., Rowlings P.A., and Horowitz M.M. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 (2001) 1598-1603
44. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., Schulz A., Thrasher A.J., Mazzolari E., Slatter M.A., Le Deist F., Blanche S., Veys P., Fasth A., Bredius R., Sedlacek P., Wulffraat N., Ortega J., Heilmann C., O'Meara A., Wachowiak J., Kalwak K., Matthes-Martin S., Gungor T., Ikinciogullari A., Landais P., Cant A.J., Friedrich W., and Fischer A. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 111 (2008) 439-445
45. Kraunus J., Schaumann D.H., Meyer J., Modlich U., Fehse B., Brandenburg G., von Laer D., Klump H., Schambach A., Bohne J., and Baum C. Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 11 (2004) 1568-1578
46. Zychlinski D., Schambach A., Modlich U., Maetzig T., Meyer J., Grassman E., Mishra A., and Baum C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16 (2008) 718-725
47. Mazurier F., Gan O.I., McKenzie J.L., Doedens M., and Dick J.E. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 103 (2004) 545-552
48. Kennedy D.R., McLellan K., Moore P.F., Henthorn P.S., and Felsburg P.J. Effect of ex vivo culture of CD34+bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 15 (2009) 662-670
49. Montini E., Cesana D., Schmidt M., Sanvito F., Bartholomae C.C., Ranzani M., Benedicenti F., Sergi L.S., Ambrosi A., Ponzoni M., Doglioni C., Di Serio C., von Kalle C., and Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119 (2009) 964-975
50. Maruggi G., Porcellini S., Facchini G., Perna S.K., Cattoglio C., Sartori D., Ambrosi A., Schambach A., Baum C., Bonini C., Bovolenta C., Mavilio F., and Recchia A. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 17 (2009) 851-856
51. Brown M.P., Topham D.J., Sangster M.Y., Zhao J., Flynn K.J., Surman S.L., Woodland D.L., Doherty P.C., Farr A.G., Pattengale P.K., and Brenner M.K. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 4 (1998) 1253-1260
52. Hartlerode A.J., and Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem. J. 423 (2009) 157-168
53. Kim Y.G., Cha J., and Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1156-1160
54. Stoddard B.L. Homing endonuclease structure and function. Q. Rev. Biophys. 38 (2005) 49-95
55. Jarjour J., West-Foyle H., Certo M.T., Hubert C.G., Doyle L., Getz M.M., Stoddard B.L., and Scharenberg A.M. High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display. Nucleic Acids Res. 37 (2009) 6871-6880
56. Lombardo A., Genovese P., Beausejour C.M., Colleoni S., Lee Y.L., Kim K.A., Ando D., Urnov F.D., Galli C., Gregory P.D., Holmes M.C., and Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25 (2007) 1298-1306